The DNDi Latin America office was opened in 2004. With the primary aim to support regional R&D activities for Chagas disease, malaria, and leishmaniasis, the Latin American office also undertakes advocacy and communications activities to increase neglected diseases awareness in the region.
www.dndial.org






DNDi in Latin America

Rua São Jose, 70 – Sala 601
20010-020
Centro – Rio de Janeiro
Brazil
Tel: +55 21 2529 0400


 


  • Completion of recruitment in the clinical study of new regimens of benznidazole monotherapy and in combination with fosravuconazole in Bolivia for the treatment of Chagas disease
  • Start of a Phase II clinical study in Spain to test short courses of fexinidazole for Chagas disease
  • Implementation of a new, simplified diagnostic algorithm and treatment for all patients with Chagas disease, including chronic patients, as part of the pilot Chagas Access Programme in Colombia
  • Start of a clinical study on cutaneous leishmaniasis combining thermotherapy with miltefosine in Colombia and Peru
  • Pilot project for access and implementation of Chagas diagnosis and treatment launches in four regions of Colombia, to boost national response in partnership with MoH.
  • Study results pave the way for treatment guidelines to change in Brazil, replacing Glucantime by AmBisome® as first-line VL treatment.
  • UNASUR (Union of South American Nations) High-Level Meeting with Health Ministry representatives discusses access to HCV treatment with DNDi participation.
  • DNDi Partners’ Meeting in Rio de Janeiro gathers 300 neglected disease R&D stakeholders to debate regional and global issues, such as innovative funding and emerging public health challenges.
  • Newly-formed Social Movement against NTDs holds first meeting in Brazil, bringing together patients and public health actors in a new advocacy focused initiative.